Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 65.25
-0.33 (-0.50%)
At close: Nov 14, 2025
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 231.30M CNY in the quarter ending September 30, 2025, with 71.46% growth. This brings the company's revenue in the last twelve months to 607.75M, up 55.98% year-over-year. In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 359.90M with 294.24% growth.
Revenue (ttm)
607.75M
Revenue Growth
+55.98%
P/S Ratio
49.51
Revenue / Employee
713.32K
Employees
852
Market Cap
30.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | 27.76M | -13.26M | -32.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |